

AstraZeneca to build bio-diagnostic innovation centre in China

30 April 2021 | News

The center is expected to initiate an integrative and patient-centric program where disease diagnosis, treatment, and rehabilitation coexist



Geneseeq Technology Inc., a precision oncology diagnostics company, and AstraZeneca, a global biopharmaceutical company, have announced their strategic collaboration to establish a Bio-Diagnostic Innovation Center in Guangzhou, China.

The center is expected to initiate an integrative and patient-centric program where disease diagnosis, treatment, and rehabilitation coexist. The center will combine Geneseeq's expertise in developing clinical diagnostics tools, with AstraZeneca's deep experience in oncology therapeutics development to produce innovative diagnostics platforms for cancer patients.

The collaboration also outlines joint efforts to build a clinical diagnostics laboratory in Guangzhou International BIO-Island.

On April 23, 2021, AstraZeneca held an opening ceremony and twelve sub-forums for its Symposium Annual Meeting in Wuxi, China. The conference emphasized several meaningful collaborations with industry, clinical, and academic research partners in major therapeutic areas such as oncology, cardiology and nephrology.

AstraZeneca's Global Executive Vice President, the President of Greater China and International Business, Lei Wang, delivered the strategic collaboration announcement between AstraZeneca and Geneseeq at the signing ceremony. He emphasized the establishment of the Bio-Diagnostics Innovation Center, and the center's planned R&D, educational, and promotional efforts to advance precision medicine access.

Under its collaboration with AstraZeneca, Geneseeq will build its fourth core laboratory in South China, in addition to its laboratories in Nanjing, Shanghai and Beijing. The two companies hope to bring highly scalable and broadly applicable clinical diagnostic tools to cancer patients soon.